Can-Fite BioPharma (NYSE:CANF) Stock Rating Lowered by StockNews.com

Can-Fite BioPharma (NYSE:CANF) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Friday.

A number of other equities research analysts also recently issued reports on CANF. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma in a research note on Thursday, December 5th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Can-Fite BioPharma in a report on Tuesday, November 12th.

Can-Fite BioPharma Stock Performance

CANF opened at $1.58 on Friday. The stock has a market capitalization of $5.59 million, a price-to-earnings ratio of -0.88 and a beta of 1.32. Can-Fite BioPharma has a fifty-two week low of $1.29 and a fifty-two week high of $4.69. The company has a fifty day moving average of $2.15 and a 200 day moving average of $2.47.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC raised its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the quarter. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.